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Abstract: Glutamate signaling is achieved by an elaborate network involving 
neurons and astrocytes. Hence, it is critical to better understand how neurons 
and astrocytes interact to coordinate the cellular regulation of glutamate 
signaling. In these studies, we used rat cortical cell cultures to examine 
whether neurons or releasable neuronal factors were capable of regulating 
system xc− (Sxc), a glutamate-releasing mechanism that is expressed 
primarily by astrocytes and has been shown to regulate synaptic 
transmission. We found that astrocytes cultured with neurons or exposed to 
neuronal-conditioned media displayed significantly higher levels of Sxc 
activity. Next, we demonstrated that the pituitary adenylate cyclase-
activating polypeptide (PACAP) may be a neuronal factor capable of regulating 
astrocytes. In support, we found that PACAP expression was restricted to 
neurons, and that PACAP receptors were expressed in astrocytes. 
Interestingly, blockade of PACAP receptors in cultures comprised of astrocytes 
and neurons significantly decreased Sxc activity to the level observed in 
purified astrocytes, whereas application of PACAP to purified astrocytes 
increased Sxc activity to the level observed in cultures comprised of neurons 
and astrocytes. Collectively, these data reveal that neurons coordinate the 
actions of glutamate-related mechanisms expressed by astrocytes, such as 
Sxc, a process that likely involves PACAP. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Neurochemistry, Vol. 137, No. 3 (May 2016): pg. 384-393. DOI. This article is © Wiley and permission has been 
granted for this version to appear in e-Publications@Marquette. Wiley does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from Wiley. 
3 
 
 
A critical gap in modeling excitatory signaling is how distinct 
components of the glutamate system expressed by neurons and 
astrocytes are coordinated. In these studies, we found that system xc− 
(Sxc), a glutamate release mechanism expressed by astrocytes, is 
regulated by releasable neuronal factors including PACAP. This 
represents a novel form of neuron–astrocyte communication, and 
highlights the possibility that pathological changes involving astrocytic 
Sxc may stem from altered neuronal activity. 
Abbreviations used 
Astro astrocyte(s) 
DIV day(s) in vitro 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
P6-38 PACAP6-38 
PACAP pituitary adenylate cyclase-activating polypeptide 
SSZ sulfasalazine 
Sxc system xc− 
TBOA DL-threo-β-hydroxyaspartic acid 
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Glutamate is often described as the primary excitatory 
neurotransmitter in the brain, in part, because it may be present in up 
to 80% of all synapses (Curtis and Johnston 1974; Choi 1988; Harris 
and Kater 1994; Meldrum 2000; Franks et al. 2002; Javitt et al. 
2011). As such, altered excitatory neurotransmission likely contributes 
to most CNS diseases (Carlsson and Carlsson 1990; Olney 1990; 
Brown and Bal-Price 2003; Hynd et al. 2004; Maragakis and Rothstein 
2004; Foster and Kemp 2006; Niswender and Conn 2010; Rondard 
and Pin 2015). While traditional models of glutamate signaling depict 
release solely from pre-synaptic terminals and diffusion throughout the 
synaptic cleft to activate pre- and post-synaptic receptors, it is 
becoming increasingly evident that excitatory neurotransmission is 
achieved by an elaborate network expressed across multiple types of 
cells that regulate signaling within and outside of the synaptic cleft 
(Herrera-Marschitz et al. 1996; Timmerman and Westerink 1997; 
Jabaudon et al. 1999; Danbolt 2001; Schoepp 2001; Baker et al. 
2002, 2003; Pirttimaki et al. 2011; Bridges et al. 2012). In support, 
astrocytes and neurons express glutamate receptors, transporters, and 
release mechanisms, and astrocyte to neuron signaling has been 
shown to be a key determinant of synaptic transmission (Porter and 
McCarthy 1996; Pasti et al. 1997; Araque et al. 1999; Fellin et al. 
2004, 2006; Perea and Araque 2005; Haydon and Carmignoto 2006; 
Panatier et al. 2011; Santello et al. 2012; Perez-Alvarez et al. 2014; 
Gomez-Gonzalo et al. 2015). Therefore, decoding the complex 
molecular and cellular regulation of glutamate could lead to novel 
opportunities to better understand and treat pathological excitatory 
signaling. 
A critical gap in modeling excitatory signaling is how distinct 
components of the glutamate system expressed by neurons and 
astrocytes are coordinated. In these experiments, we tested the 
hypothesis that neurons regulate the activity of glutamate-related 
mechanisms expressed by astrocytes. To do this, we examined the 
neuronal regulation of system xc− (Sxc), a non-canonical glutamate-
release mechanism primarily expressed by astrocytes (Bannai and 
Kitamura 1980, 1981; Sato et al. 1999; Pow 2001; Zhang et al. 
2014). 
Sxc is a key component of glutamate signaling that is implicated 
in the pathology or treatment of multiple CNS diseases. It contributes 
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to glutamate signaling by coupling the release of non-vesicular 
glutamate to the intracellular transport of cystine (Bannai and 
Kitamura 1980, 1981; Sato et al. 1999). Manipulations that increase 
Sxc activity have been shown to (i) influence multiple aspects of 
synaptic transmission and plasticity (Baker et al. 2002; Xi et al. 2002; 
Moran et al. 2005; Moussawi et al. 2009, 2011; Kupchik et al. 2012), 
(ii) normalize behavior in pre-clinical disease models (Baker et al. 
2003, 2008; Madayag et al. 2007; Knackstedt et al. 2010; Alajaji et al. 
2013; Lutgen et al. 2013), and (iii) exert therapeutic effects against 
multiple CNS diseases including drug addiction and schizophrenia 
(Berk et al. 2008; Amen et al. 2011; Lewerenz et al. 2013; Canavan 
et al. 2014; Verrico et al. 2014). Unfortunately, the regulation of Sxc 
is poorly understood. 
In these studies, our primary objective was to evaluate the 
possibility that neurons regulate astrocyte Sxc activity. In addition, we 
tested the hypothesis that the pituitary adenylate cyclase-activating 
peptide (PACAP) is a neuronal factor capable of regulating astrocyte 
Sxc activity. To do this, we verified that PACAP is expressed by rat 
cortical neurons and not astrocytes, and that rat cortical astrocytes 
express PACAP receptors. We then found that application of PACAP to 
cortical astrocytes increased Sxc activity. Moreover, inhibition of 
PACAP signaling blocked neuron-induced up-regulation of Sxc. 
Collectively, these data are consistent with the possibility that altered 
neuronal activity could give rise to pathological changes in astrocyte 
functions, including altered Sxc activity which may be present in 
numerous CNS disorders ranging from drug addiction to schizophrenia. 
Material and methods 
Animals and materials 
These experiments utilized cortical tissues obtained from 
Sprague–Dawley rats (age was gestational day 15–16 or post-natal 
day 3–4; sex was undetermined; Envigo, Indianapolis, IN, USA). 
Experimental procedures were approved by the Marquette University 
Institutional Animal Care and Use Committee. The primary materials 
included fetal bovine serum and horse serum (Atlanta Biologicals, 
Lawrenceville, GA, USA), 14C-cystine (PerkinElmer, Waltham, MA, 
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USA), PACAP1-38 (California Peptide Research, Napa, CA, USA), and 
PACAP6-38 (P6-38; Anaspec, Fremont, CA, USA). PACAP1-38 (PACAP) is 
the endogenous full-length peptide, whereas P6-38 is a truncated 
version of PACAP and inhibits PACAP receptors (Miyata et al. 1989; 
Robberecht et al. 1992; Arimura 2007; Vaudry et al. 2009). 
Cell culture procedures 
Purified cortical astrocyte cultures 
Purified cortical astrocyte cultures were prepared from post-
natal day 3–4 rat pups. In brief, cortical cells were disassociated and 
then suspended in Neurobasal A media (Thermo Fisher Scientific, 
Waltham, MA, USA) supplemented with 10% fetal bovine serum and 
1% Glutamax (Thermo Fisher Scientific). Cells were initially grown in 
25 cm2 or 75 cm2 cell culture flasks. Once confluent, cells were then 
subjected to prolonged, orbital shaking (250 rpm, approximately 7 g, 
for 18 h at 37°C), which has been used to yield purified astrocyte 
cultures (McCarthy and de Vellis 1980). Purified astrocytes were then 
plated on 24-well plates, and refreshed with 70% new culture media 
every 2–3 days. 
Purified cortical neuronal cultures 
Purified cortical neuronal cultures were prepared from 
embryonic rat cortical tissue (gestational day 15–16) as previously 
described (Lobner 2000). In brief, dissociated cells were suspended in 
Eagles’ minimal essential medium (Earle's salts, glutamine-free) 
supplemented with glutamine (2 mM), glucose (21 mM), horse serum 
(5%), and fetal bovine serum (5%). Cells were seeded on 24-well 
plates. Forty-eight hours later, cytosine arabinoside (at a final 
concentration of 10 μM) was added to the culture media to inhibit glial 
reproduction (Dugan et al. 1995). Neurons were then grown for an 
additional 11–13 days. 
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Mixed neuronal and glial cultures 
Procedure for preparing mixed cultures was identical to that of 
obtaining neuronal cultures (see above) except that cytosine 
arabinoside was not added to the culture media. 
Physically separated astrocyte and neuronal cultures 
Because the above mixed cultures also contained a limited 
number of non-astrocyte glial cells, and to determine whether neuron–
astrocyte communication involves the release of a neuronal factor, we 
utilized a ‘non-contact’ co-culture system in which purified astrocytes 
were physically separated from purified neurons. Note, these cells are 
referenced in this study as Astrocytes + neuronal-conditioned media 
(NCM). In these experiments, purified astrocytes were obtained as 
described above. When astrocytes reached confluency after 13–
16 days in vitro (DIV), neuronal cultures were seeded on removable 
inserts (Corning, Corning, NY, USA) that had been placed into the 
wells containing astrocytes, such that both cell types were immersed 
in the media but were not in physical contact. Fourteen days later, 
downstream experiments to examine the effects of neurons on 
astrocytes were performed upon removal of the neuronal inserts. As a 
result, the DIV for these cells was 27–30. 
All cell-growing surfaces in culture flasks and 24-well plates 
were pre-coated with poly-d-lysine (10 mg/L) and laminin (0.4 mg/L). 
All cell cultures were maintained in humidified 5% CO2 incubators at 
37°C. 
14C-cystine uptake assay 
The assessment of system xc− (Sxc) activity is often achieved by 
measuring intracellular uptake of radiolabeled cystine as this is 
primarily dependent on Sxc (Liu et al. 2009, 2014; Resch et al. 2014; 
Albano et al. 2015). Note, we demonstrated that over 85% of 14C-
cystine uptake in our cells was blocked by the Sxc inhibitor 
sulfasalazine (SSZ; see Fig. 3b). In contrast, extracellular glutamate is 
an insensitive indicator of Sxc as this is a product of numerous 
mechanisms (Swanson et al. 1997; Duan et al. 1999; Perego et al. 
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2000; Montana et al. 2004; Hires et al. 2008). Radiolabeled cystine 
uptake assays were performed as described previously with minor 
modifications (Liu et al. 2009). In brief, experiments were conducted 
in a bead bath at 37°C. Cells were washed three times with warm 
HEPES-buffered saline solution, after which 14C-cystine was added to 
the media for 20 min at a final concentration of 0.3 μM. This 
concentration was used as it is similar to extracellular cystine 
concentrations in the brain (Baker et al. 2003). DL-threo-β-
hydroxyaspartic acid (10 μM) was added to the culture media to 
prevent 14C-cystine uptake by sodium-dependent glutamate 
transporters. As described below, some of the experiments also 
involved the addition of the Sxc inhibitor SSZ (300 μM), PACAP, or P6-
38. After incubating cells with 14C-cystine, cells were washed three 
times with ice-cold HEPES-buffered saline solution, and then 
solubilized with 1M NaOH solution. One aliquot of cell lysate was used 
for protein determination using a bicinchoninic acid protein assay, and 
another aliquot was used for scintillation counting to measure the level 
of 14C-cystine uptake. 14C-cystine content was normalized to protein 
concentration. Data are presented as CPM/μg of protein. 
RNA extraction and cDNA construction 
Total RNA was isolated from cell cultures with Trizol Reagent 
(Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. 
DNase treatment was applied to all RNA samples to remove potential 
genomic DNA contamination with a DNA-free kit (Life Technologies, 
Carlsbad, CA, USA). Assessment of RNA purity and quantity was 
performed on a NanoVue Plus Spectrophotometer (GE life sciences, 
Pittsburg, PA, USA). cDNA was constructed from total RNA using the 
Reverse Transcription System (Promega, Madison, WI, USA) with 
oligo(dT) primers following the manufacturer's protocol. 
Real-time quantitative PCR 
Quantitative PCR was performed using a StepOne Real-Time 
PCR System (Applied Biosystems, Carlsbad, CA, USA) and PerfeCTa 
SYBR Green FastMix with ROX (Quanta Biosciences, Gaithersberg, MD, 
USA). Relative quantification of target gene expression was normalized 
to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 
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(GAPDH) using the ∆∆Ct method (Schmittgen and Livak 2008). Primer 
sequences were as follows: xCT (catalytic subunit of Sxc) forward – 5′-
AGGGCATACTCCAGAACACG-3′; xCT reverse – 5′-
ATGCTCGTACCCAATTCAGC-3′; PACAP forward – 5′-
AACCCGCTGCAAGACTTCTA-3′; PACAP reverse – 5′-
CTTTGCGGTAGGCTTCGTTA-3′; PAC1R forward – 5′-
TGCCTGTGGCTATTGCTATG-3′; PAC1R reverse – 5′-
TTTAGTCCCATCAGGTCGTTG-3′; GAPDH forward – 5′-
CTCCCATTCTTCCACCTTTGA-3′; and GAPDH reverse – 5′-
ATGTAGGCCATGAGGTCCAC-3′. Primers were designed to be intron 
spanning using the online primer design tool Primer3 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi). A single 
product from amplification was confirmed by melt curve analysis. 
Amplification efficiency of all genes was determined to be 
approximately 95%. 
Statistics 
Statistical analyses were performed using spss Statistics 
(Version 19; IBM, Armonk, NY, USA). Analysis of variance (anova) was 
used when comparing data sets that included more than two groups. 
Bonferroni tests were used for subsequent post hoc analyses of 
significant effects involving more than two groups. Student's t-tests 
were used when comparing results from only two groups. In all 
instances, statistical significance was designated as p < 0.05. 
Experiment 1: Neuronal regulation of Sxc 
The goal of this experiment was to test the hypothesis that a 
releasable neuronal factor regulates Sxc activity in astrocytes. To do 
this, we used two distinct approaches to co-express rat cortical 
neurons and astrocytes in culture. First, we measured 14C-cystine 
uptake in rat mixed cortical cultures (DIV 13–16). The advantage of 
this approach is that astrocytes are continuously grown in the 
presence of neurons. A disadvantage of this approach is that these 
cultures contain a limited number of microglia and oligodendrocytes. 
In addition, neurons physically contact astrocytes in these cultures. To 
address these two points, we also measured 14C-cystine uptake by 
astrocytes that had been exposed to neuron-conditioned media. To do 
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this, we first generated purified astrocyte cultures as described above. 
When astrocytes reached confluency (typically 13–16 DIV), neuronal 
cultures were seeded on removable inserts which were placed into the 
wells containing astrocytes, such that both cell types were co-cultured 
yet with no physical contact. Fourteen days later, the neuronal inserts 
were removed, and 14C-cystine uptake was measured as described 
above. Note, the 14-day period represents the time needed for the 
neurons to mature. The control cells in this experiment were purified 
astrocyte cultures in which the inserts lacked neurons. Tests using 
these cells occurred on DIV 27–30. 
Experiment 2: Neuronal up-regulation of Sxc requires PACAP 
receptor signaling 
In an effort to begin to unmask the molecular basis of neuron–
astrocyte signaling that regulates Sxc, we examined the impact of 
inhibiting PACAP receptors on cystine uptake in rat cortical cultures. 
Our interest in PACAP stems from previous studies showing that 
stimulation of PACAP receptors increases the activity of Sxc and GLT-1 
(Figiel and Engele 2000; Resch et al. 2014), both of which are 
primarily expressed by astrocytes (Rothstein et al. 1994, 1996; Lehre 
et al. 1995; Torp et al. 1997; Pow 2001; Zhang et al. 2014). In this 
experiment, vehicle or 10 μM P6-38 (see Figiel and Engele 2000 for 
concentration justification) was applied to rat cortical cultures (DIV 
13–16) for 60 min, at which point 14C-cystine uptake was measured as 
described above. 
Experiment 3: PACAP up-regulates Sxc on astrocytes 
In this experiment, we tested the hypothesis that exogenous 
application of PACAP would significantly up-regulate Sxc activity in 
purified astrocyte cultures. To test this, PACAP (0–100 nM) was 
applied to purified astrocyte cultures (DIV 13–16) for 24 h. Afterward, 
14C-cystine uptake was measured as described above. This experiment 
was also conducted in purified neuronal and mixed cortical cultures, 
although the predicted outcome was less certain given the likely 
expression of endogenous PACAP in these cultures. 
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Experiment 4: Cellular distribution of PACAP and PAC1R in rat 
cortical cultures 
To further examine the possibility that PACAP is a neuronal 
factor capable of regulating astrocytes, we examined the cellular 
expression patterns of PACAP and its primary receptor, PAC1R. We 
were specifically interested in determining whether PACAP was solely 
expressed in neurons and PAC1R in purified astrocytes. To do this, we 
used RT-qPCR to measure mRNA expression for PACAP and PAC1R in 
mixed cultures, purified astrocyte cultures, and purified neuronal 
cultures (DIV 13–16). 
Experiment 5: Regulation of xCT mRNA by neurons and the 
neuronal factor PACAP 
To better understand the observed up-regulation of astrocyte 
Sxc by neurons or PACAP, we measured xCT mRNA in purified 
astrocytes and mixed cultures, purified astrocytes ± neuronal-
conditioned media, and purified astrocytes ± PACAP. 
Results 
Experiment 1: Neuronal regulation of Sxc 
To determine whether neurons are capable of regulating 
astrocyte Sxc activity, we used two approaches to permit neuron–
astrocyte signaling. First, astrocyte and neurons were co-cultured 
upon plating (mixed cultures). This approach is designated in Fig. 1 as 
DIV 13–16, which refers to the number of days the cells had been 
cultured. In addition, confluent, purified astrocyte cultures were 
exposed to neuronal conditioned media (NCM) by placing neurons 
grown onto an insert into the wells containing the astrocytes for 
14 days (as described in the methods for Experiment 1). This approach 
is designated in Fig. 1 as DIV 27–30. A univariate anova with DIV and 
culture cellular composition (i.e., astrocytes only or mixed or astrocyte 
+ NCM) as between-subject factors produced a main effect of cell 
composition [Fig. 1; F(1,36) = 77.979, p < 0.001] but not a main 
effect of DIV or an interaction between these variables. These findings 
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illustrate that a releasable neuronal factor significantly up-regulates 
Sxc activity on astrocytes (see Fig. 1). 
 
Figure 1. Neurons up-regulate Sxc activity in astrocytes. Data depict the mean ± SEM 
levels of 14C-cystine measured in rat cortical cells (N = 8–12/condition) that had been 
cultured for 13–16 or 27–30 days in vitro (DIV). Astro, astrocytes; NCM, neuronal-
conditioned media. *Represents a significant difference from corresponding purified 
astrocytes, p < 0.001. 
Experiment 2: Neuronal up-regulation of Sxc requires 
PACAP receptor signaling 
Previous studies have shown that PACAP increases the activity 
of Sxc and GLT-1 (Figiel and Engele 2000; Resch et al. 2014), both of 
which are primarily expressed by astrocytes (Rothstein et al. 1994, 
1996; Lehre et al. 1995; Torp et al. 1997; Pow 2001; Zhang et al. 
2014). In an effort to reveal the molecular basis of neuron–astrocyte 
signaling that regulates Sxc, we examined the impact of inhibiting 
PACAP receptors with P6-38 on 14C-cystine uptake in rat mixed, purified 
astrocyte, and purified neuronal cortical cultures. A univariate anova 
with cell composition and P6-38 treatment (0 or 10 μM) as between-
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subject variables yielded a significant interaction [Fig. 2; 
F(2,62) = 73.849, p < 0.001]. To deconstruct the interaction, we 
compared 14C-cystine levels in vehicle-treated mixed cultures to every 
other condition. We found that vehicle-treated cultures containing 
neurons and astrocytes (i.e., mixed) displayed significantly higher 
levels of 14C-cystine, and that this effect was blocked by inhibiting 
PACAP receptors with P6-38 (Bonferroni, p < 0.001). Interestingly, P6-38 
did not alter 14C-cystine levels in purified astrocyte or in purified 
neuronal cultures. These data suggest that endogenous PACAP-
induced up-regulation of Sxc activity is only present in mixed cortical 
cultures (see Fig. 2). 
 
Figure 2. Inhibition of pituitary adenylate cyclase-activating polypeptide (PACAP) 
receptors blocks neuron-induced up-regulation of Sxc. Data depict the uptake of 14C-
cystine in rat cortical cultures in the presence or absence of the PACAP receptor 
inhibitor P6-38 (vehicle or 10 μM; N = 6–12/condition). *Indicates a significant 
difference relative to vehicle-treated mixed cortical cultures, Bonferroni, p < 0.001. 
Experiment 3: PACAP up-regulates Sxc on astrocytes 
To confirm that PACAP promotes Sxc activity in rat cortical 
astrocytes, we compared 14C-cystine uptake in mixed cultures, purified 
astrocyte cultures, and purified neuronal cultures following PACAP 
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application (24 h) in the presence or absence of the Sxc inhibitor SSZ. 
A univariate anova with culture cell composition and PACAP treatment 
as between-subject factors produced a significant interaction [Fig. 3a; 
F(4,62) = 31.958, p < 0.001]. To further analyze the data, we 
examined the impact of PACAP on 14C-cystine uptake in each type of 
culture. A significant, simple, main effect of PACAP treatment was 
obtained only in purified astrocyte cultures [F(2,21) = 75.904, 
p < 0.001]. Subsequent post hoc analyses revealed that PACAP 
increased uptake at 10 and 100 nM (Bonferroni, p < 0.001). 
 
Figure 3. Pituitary adenylate cyclase-activating polypeptide (PACAP) up-regulates Sxc 
activity in cortical astrocytes only. (a) Data depict mean ± SEM levels of 14C-cystine in 
rat cortical cell cultures after 24 h PACAP treatment (0–100 nM; N = 8/condition). 
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*Indicates a significant difference relative to vehicle-treated purified astrocyte 
cultures, Bonferroni, p < 0.001. (b) Data depict mean ± SEM levels of 14C-cystine in 
rat purified astrocyte cultures after 24 h PACAP (0 or 100 nM) assessed in the 
presence of an Sxc inhibitor sulfasalazine (SSZ, 0 or 300 μM; N = 4/condition). 
*Indicates a significant difference relative to PACAP vehicle-treated cells that were not 
exposed to SSZ (-SSZ), Bonferroni p < 0.001. 
Although Sxc is primarily associated with astrocytes, we verified 
that PACAP-induced increases in 14C-cystine uptake reflect Sxc activity. 
To do this, we assessed the impact of PACAP on 14C-cystine uptake by 
astrocytes in the presence and absence of the Sxc inhibitor SSZ. A 
univariate anova with PACAP and SSZ treatments as between-subject 
factors resulted in a significant interaction [Fig. 3b; F(1,12) = 19.130, 
p < 0.01]. Post hoc analyses indicated that PACAP increased 14C-
cystine uptake in astrocytes when tested in the absence (Bonferroni, 
p < 0.001) but not in the presence of SSZ. 
Experiment 4: Cellular distribution of PACAP and PAC1R 
in rat cortical cultures 
To further examine the possibility that PACAP is a neuronal 
factor capable of regulating astrocytes, we assessed the cellular 
expression patterns of PACAP and its primary receptor, PAC1R 
(Gottschall et al. 1990; Lam et al. 1990). A one-way anova with 
culture cell composition as a between-subject factor yielded a main 
effect on PACAP mRNA levels [Fig. 4a; F(2,17) = 294.774, p < 0.001]. 
Post hoc analyses revealed that mixed and purified neuronal cultures 
expressed the highest levels of PACAP mRNA (Bonferroni, p < 0.001). 
In fact, PACAP mRNA was not detectable in purified astrocyte cultures 
(Fig. 4a). A one-way anova comparing the cellular distribution of 
PAC1R mRNA yielded a main effect of cell type [Fig. 4b; 
F(2,17) = 93.863, p < 0.001]. Post hoc analyses revealed expression 
of PAC1R in every cell type, but with the highest levels evident in 
mixed cortical cultures (Bonferroni, p < 0.001). Collectively, these 
results demonstrate that in rat cortical cultures, PACAP is solely 
expressed in neurons and its primary receptor, PAC1R, is expressed by 
astrocytes. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Neurochemistry, Vol. 137, No. 3 (May 2016): pg. 384-393. DOI. This article is © Wiley and permission has been 
granted for this version to appear in e-Publications@Marquette. Wiley does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from Wiley. 
16 
 
 
Figure 4. The cellular expression patterns of pituitary adenylate cyclase-activating 
polypeptide (PACAP) and its primary receptor, PAC1R, support the possibility that 
PACAP is a neuropeptide capable of regulating astrocyte Sxc activity. (a) Data depict 
mean ± SEM levels of PACAP mRNA in rat cortical cells cultures (N = 5–8/cell type). 
*Indicates a significant difference relative to mixed cultures, Bonferroni, p < 0.001. 
#Indicates a significant difference relative to purified astrocyte cultures, Bonferroni, 
p < 0.001. (b) Data depict mean ± SEM levels of PAC1R mRNA in rat purified 
astrocyte and neuronal cultures relative to that in cortical mixed cell cultures (N = 5–
8/cell type). *Indicates a significant difference relative to mixed cultures, Bonferroni, 
p < 0.001. 
Experiment 5: Neurons and PACAP increase xCT mRNA 
To better understand the observed up-regulation of astrocyte 
Sxc activity by neurons or PACAP, we measured mRNA levels of xCT, 
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the functional subunit of Sxc (Sato et al. 1999, 2000; Bridges et al. 
2001). Mixed cultures of astrocytes and neurons [t(6) = 17.734, 
p < 0.001], as well as purified astrocyte cultures exposed to NCM 
[t(13) = 13.431, p < 0.001], expressed significantly higher levels of 
xCT mRNA relative to respective controls (Fig. 5). Similarly, PACAP 
application in purified astrocytes also robustly increased xCT mRNA 
[Fig. 5; t(10) = 16.554, p < 0.001]. Together, these results suggest 
that the up-regulation of astrocyte Sxc by neurons or PACAP may 
involve increased Sxc expression. 
 
Figure 5. Exposure to neurons and pituitary adenylate cyclase-activating polypeptide 
(PACAP) increases xCT mRNA in cultured cortical astrocytes. Data depict mean ± SEM 
levels of xCT mRNA (normalized to respective controls) in rat cortical cells cultures 
(N = 4–12/condition). Astro refers to purified astrocyte cultures; mixed cells refer to 
cultures comprised of neurons and astrocytes; neuronal-conditioned media (NCM) 
refers to neuronal-conditioned media achieved by placing neurons grown on inserts 
into the culture wells containing astrocytes for 14 days; PACAP treatment was for 24 h 
at 10 nM. *Indicates a significant difference relative to the respective control, t-test, 
p < 0.001. 
  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Neurochemistry, Vol. 137, No. 3 (May 2016): pg. 384-393. DOI. This article is © Wiley and permission has been 
granted for this version to appear in e-Publications@Marquette. Wiley does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from Wiley. 
18 
 
Discussion 
Glutamate signaling is achieved by an elaborate network likely 
requiring coordinated activity between neurons and astrocytes. In 
support, both cells express glutamate receptors, transporters, and 
release mechanisms (Choi 1988; Greenamyre et al. 1988; Coyle and 
Puttfarcken 1993; Moghaddam and Adams 1998; Araque et al. 1999, 
2014; Tapia et al. 1999; Marino et al. 2001; Franks et al. 2003; 
Haydon and Carmignoto 2006; Javitt et al. 2011; Santello et al. 2012; 
Perez-Alvarez et al. 2014). The purpose of these experiments was to 
determine whether, and how, neurons regulate components of the 
glutamate system expressed by astrocytes. To do this, we focused on 
system xc− (Sxc) as this non-canonical release mechanism has been 
shown to be expressed primarily by astrocytes (Bannai and Kitamura 
1980, 1981; Sato et al. 1999; Pow 2001; Zhang et al. 2014), 
significantly contributes to glutamate homeostasis (Baker et al. 2002; 
Xi et al. 2002; Melendez et al. 2005), regulates neuronal activity (Xi 
et al. 2002; Moran et al. 2005; Moussawi et al. 2009, 2011; Moussawi 
and Kalivas 2010; Kupchik et al. 2012), and has been linked to 
multiple CNS diseases (Bridges et al. 2012; Lewerenz et al. 2013; 
Deepmala et al. 2015). Our major finding is that Sxc activity is 
significantly increased when astrocytes are exposed to neurons or to 
neuronal factors, including pituitary adenylate cyclase-activating 
peptide (PACAP). These findings are significant, in part, because they 
illustrate a novel form of neuron–astrocyte communication. Hence, 
pathological changes involving components of the glutamate system 
expressed by astrocytes, such as Sxc, may stem from aberrant activity 
of neuronal circuits. 
Neuronal regulation of Sxc 
In these studies, we found that the uptake of 14C-cystine was 
higher in rat cortical cultures comprised of neurons and astrocytes 
relative to purified astrocyte cultures. One interpretation of these data 
is that neurons up-regulate Sxc activity in astrocytes. This conclusion, 
along with findings that neurons are critical in regulating the 
expression and activity of sodium-dependent glutamate transporters 
(Swanson et al. 1997; Figiel and Engele 2000), highlights the need for 
neurons and astrocytes to display coordinated activity to achieve 
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normal glutamate signaling. Alternative interpretations of our data 
include the possibility that neurons indirectly regulate Sxc activity. For 
example, neurons may influence the development of astrocytes, which 
may in turn influence Sxc. 
To more directly test the hypothesis that a releasable neuronal 
factor coordinates Sxc activity on astrocytes, we evaluated the impact 
of neuronal-conditioned media on 14C-cystine uptake in cortical 
astrocytes. In this experiment, purified astrocyte cultures were 
conditioned to neurons through a non-contact co-culture system, in 
which neurons seeded on removable inserts were placed in astrocyte 
cultures for 14 days. Afterward, the neuronal inserts were removed to 
measure 14C-cystine uptake into astrocytes. Similar to our earlier 
finding, we found that cortical astrocytes that were exposed to 
neuronal-conditioned media displayed significantly higher 14C-cystine 
uptake. We did not observe any other difference in the astrocyte 
cultures exposed to neuronal-conditioned media from those lacking 
neurons. For example, the protein counts (mean ± SEM: astrocytes, 
267.1 ± 6.8 μg/mL; astrocytes exposed to NCM, 254.4 ± 6.0 μg/mL) 
or cell confluency did not differ. As a result, these findings support the 
conclusion that neurons are capable of regulating components of the 
glutamate system expressed on astrocytes. 
Regulation of Sxc by the neuropeptide PACAP 
In an attempt to identify potential neuronal factors capable of 
regulating Sxc on astrocytes, we examined the possible involvement of 
PACAP as this peptide has been shown to be expressed by cortical 
neurons (Koves et al. 1991; Waschek et al. 1998; Figiel and Engele 
2000) and capable of regulating components of the glutamate system 
expressed by astrocytes, including glutamate transporters GLT-1 and 
GLAST, in rat cortical glial cultures and Sxc in mouse glial cultures 
(Figiel and Engele 2000; Resch et al. 2014). We sought to extend 
these studies by examining whether neuron-induced up-regulation of 
14C-cystine uptake requires PACAP signaling. Application of P6-38, a 
truncated version of PACAP that inhibits PACAP receptors including 
PAC1R and VPAC2R, and also cocaine-amphetamine regulated 
transcript (CART) receptor (Robberecht et al. 1992; Gourlet et al. 
1995; Laburthe et al. 2007; Hawke et al. 2009; Mounien et al. 2009; 
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Lin et al. 2011), decreased 14C-cystine uptake in mixed cortical 
cultures to the level observed in purified astrocyte cultures. 
Interestingly, P6-38 did not alter 14C-cystine uptake in purified 
astrocytes or neurons. The results obtained in purified neuronal 
cultures likely reflect the relative lack of Sxc activity in these cells, 
although it should be noted that low amounts of 14C-cystine are 
detected in these cells. The lack of a P6-38 effect in purified astrocytes 
indicates the lack of endogenous PACAP signaling in these cells. 
Collectively, these data indicate that neuron-induced regulation of Sxc 
may involve PACAP signaling. 
To further evaluate the conclusion that PACAP is a neuropeptide 
capable of directly regulating astrocytes, we examined the cellular 
distribution of mRNA for PACAP and its primary receptor, PAC1R. 
PACAP mRNA expression in cortical cultures was restricted to neurons, 
thereby establishing PACAP as a neuropeptide in these cultures. In 
contrast, both cortical neurons and astrocytes express mRNA for 
PAC1R, which has been shown to be the most abundant PACAP 
receptor that is expressed in cortical astrocytes (Zhang et al. 2014). 
However, PACAP also stimulates VPAC1 and VPAC2 receptors, which 
are also expressed by astrocytes (Grimaldi and Cavallaro 1999). 
Hence, there is a need to identify the receptor(s) that contributes to 
the regulation of Sxc by PACAP. Interestingly, we found significantly 
higher levels of PACAP and PAC1R in mixed cultures comprised of 
neurons and astrocytes, compared to either cell type cultured alone, 
which may suggest that astrocytes influence the neuronal PACAP 
system, although changes in mRNA do not always result in changes in 
protein expression and function. While future experiments are needed 
to further explore the potential for astrocyte–neuron communication to 
be an important determinant of PACAP signaling, our extant results are 
consistent with the possibility that PACAP is a neuropeptide capable of 
regulating components of the glutamate system expressed by 
astrocytes. 
Next, we directly tested the hypothesis that PACAP application 
increases Sxc activity in astrocytes. We found that PACAP application 
significantly increased 14C-cystine uptake in rat cortical astrocytes, but 
not in mixed or purified neuronal cultures. While we anticipated 
PACAP-induced increases in 14C-cystine uptake in rat cortical 
astrocytes and a lack of an increase in purified neuronal cultures as 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Neurochemistry, Vol. 137, No. 3 (May 2016): pg. 384-393. DOI. This article is © Wiley and permission has been 
granted for this version to appear in e-Publications@Marquette. Wiley does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from Wiley. 
21 
 
these cells generally display little-to-no Sxc activity, we expected a 
modest increase in the mixed cortical cultures, an outcome we 
previously observed in mouse cultures (Resch et al. 2014). Aside from 
species, the difference between these studies is not clear, but likely 
reflects the existence of endogenous PACAP signaling. Collectively, 
these results are consistent with PACAP functioning as a neuronal 
factor controlling glutamate signaling involving astrocytes. 
The nature of PACAP-induced regulation of Sxc in astrocytes is 
likely complex. For example, we found evidence that application of 
PACAP for 24 h increased mRNA of xCT, the active subunit for Sxc. 
While increases in mRNA do not always result in augmented protein, it 
is important to note that PACAP also up-regulated Sxc activity. 
Furthermore, elevated xCT mRNA and increased Sxc activity were also 
evident in astrocytes cultured with neurons. Collectively, these data 
suggest that neurons influence the expression of Sxc in astrocytes. In 
addition, however, we found that relatively brief inhibition of PACAP 
signaling (i.e., 60 min) produced a significant reduction in Sxc activity, 
which suggests the possibility of post-translational modification. 
Additional studies are needed to better understand neuron- or PACAP-
induced regulation of Sxc. 
Altered glutamate signaling likely underlies, at least in part, 
many disorders of the brain. Hence, it is critical to better understand 
how coordinated activity across distinct cell types involved in the 
transmission of this amino acid is achieved. For example, Sxc has been 
implicated in several CNS diseases (Baker et al. 2003, 2008; Chung 
et al. 2005; Madayag et al. 2007; Knackstedt et al. 2010; Bridges 
et al. 2012; Lewerenz et al. 2013; Lutgen et al. 2013; Albano et al. 
2015; Ching et al. 2015; Deepmala et al. 2015). Similarly, altered 
activity of GLT-1 and other glutamate transporters expressed by 
astrocytes has also been implicated in pathological glutamate 
transmission (Soni et al. 2014; Jensen et al. 2015; Roberts-Wolfe and 
Kalivas 2015). In each case, however, it is unclear how glutamate 
signaling involving astrocytes may be altered. Collectively, these 
studies indicate that aberrant neural activity may be a novel factor 
underlying pathological changes in glutamate stemming from altered 
regulation of astrocytes. Moreover, PACAP itself is especially 
interesting in this regard as it has been shown to regulate glutamate 
uptake and release by astrocytes. 
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